natgillin/translations-raw huggingface dataset:
By the term "calculated as the base form" is meant that the amount of venlafaxine which is not present in the free base form, e.g. in form of the preferred hydrochloride form, has to be converted into the corresponding amount of the free base form. 
Pod terminom "što je izračunato za slobodnu bazu" misli se da količinu venlafaksina koja nije prisutna u obliku slobodne baze, primjerice u obliku poželjnog hidrokloridnog oblika, treba prevesti u odgovarajuću količinu slobodne baze.
A compound of claim 1 selected from and and therapeutically acceptable salts and/or enriched optical isomers thereof. 
Spoj patentnog zahtjeva 1 izabran iz HR P20140895 T1 1 terapeutski prihvatljive soli i/ili njihovi obogaćeni optički izomeri.
The diphenyl sulfide derivative according to claim 1, or a pharmaceutically acceptable salt or hydrate thereof, wherein the compound represented by the general formula (1) is represented by the general formula (1c), wherein in the formula (1c), R1 and R2 are as defined above. 
Derivat difenil-sulfida u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol ili hidrat, naznačen time što je spoj prikazan općom formulom (1) prikazan općom formulom (1c), [image], gdje su u formuli (1c) R1 i R2 definirani kao gore.
A method for the treatment of inflammatory diseases, including autoimmune diseases, tumours, diseases due to abnormal activation of growth factor FGF-2, female fertility disorders, tissue infarct and bone or cartilage diseases comprising administering a medicament containing deglycosylated long pentraxin PTX3 according to claim 1 . 
Primjena deglikoziliranog dugog pentraksina PTX3 prema zahtjevu 1 ili 3 ili desijalidiranog dugog pentraksina prema zahtjevu 2 za dobivanje lijeka za prevenciju ili liječenje upalnih bolesti uključujući autoimune bolesti, tumore, bolesti uslijed abnormalno aktivacije faktora rasta FGF-2, poremećaje plodnosti kod žena, infarkt tkiva i bolesti kostiju ili hrskavice.
The single layer biodegradable sheet of claim 2 for the preparation of a liquid receptacle. 
Višeslojna biorazgradiva folija prema jednom od zahtjeva 1-4 za spravljanje spremnika za tekućine.
The kit according to claim 66, wherein said cytotoxic conjugate comprises wherein a humanized version of the murine antibody DS6 or an epitope-binding fragment thereof as the cell binding agent and DM1 or DM4 as the cytotoxic agent. 
Kit prema zahtjevu 69, naznačen time što citotoksični konjugat iz smjese za liječenje obuhvaća humaniziranu verziju mišjeg protutijela DS6 ili njegov fragment koji se veže za epitop kao tvar koja se veže za stanicu te DM1 ili DM4 kao citotoksičnu tvar.
The dihydrospiro-[cycloalkylamine]-pyrimidone derivative according to claim 2, wherein R1 represents an unsubstituted 4-pyridinyl group or unsubstituted 4-pyrimidinyl group. The dihydrospiro-[cycloalkylamine]-pyrimidone derivative according to claim 3, wherein 
Dihidrospiro[cikloalkilamin|pirimidonski derivat, ili njegova sol, ili njen solvat ili hidrat, prema patentnom zahtjevu 1 ili 2, naznačen time što R1 predstavlja nesupstituiranu 4-piridinilnu skupinu ili nesupstituiranu 4- pirimidinilnu skupinu.
A process according to claim 1 wherein step b is carried out by reacting a compound of formula IIa with 2-bromo-4-fluorophenol in the presence of a phosphine and an aza compound under Mitsunobu conditions to give a compound of formula IIIa in the form of diastereomeric mixture. 
Postupak prema zahtjevima 1 do 4, naznačen time da se koraci b/m provode reakcijom smjese formule Ila ili IIb sa 2-bromo-4-fluorofenolom u prisutnosti fosfina i aza spoja pod uvjetima Mitsunobu, da bi se dobio spoj formule IIIa i NIb u obliku dijasteromerne smjese.
Particularly preferred examples of pharmacologically acceptable acid addition salts of the PDE4 inhibitors are the pharmaceutically acceptable salts which are selected from among the salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, 1-hydroxy-2-naphthalenecarboxylic acid, or maleic acid. 
Sljedeće kiseline mogu se smatrati reprezentativnim primjerima prikladnih kiselina za tvorbu adicijskih soli B2-agonista: klorovodična kiselina, bromovodična kiselina, sumporna kiselina, fosforna kiselina, metansuifonska kiselina, octena kiselina, fumarna kiselina, sukcinska kiselina, mliječna kiselina, limunska kiselina, maleinska kiselina i trifluoroctena kiselina.
no more than three positions within the seed sequence; and 
(i) nema više od tri pozicije unutar sekvence zametka; i
A T cell genetically modified to express a CAR wherein the CAR comprises (a) an antigen binding domain that is an anti-CD 19 scFv, (b) a costimulatory 4-1BB signaling region, and (c) a CD3 zeta signaling domain, for use in a method for treating cancer in a human, wherein the anti-CD19 scFv comprises the amino acid sequence of SEQ ID NO:20, and wherein the human is resistant to at least one chemotherapeutic agent. 
T stanica koja je genetski modificirana tako da eksprimira CAR, naznačena time što CAR sadrži (a) antigen vezujuću domenu koja je anti-CD19 scFv, (b) kostimulatorno signalno područje 4-1BB, i (c) signalnu domenu CD3 zeta za upotrebu u postupku za liječenje raka kod čovjeka, pri čemu anti-CD19 scFv sadrži aminokiselinsku sekvencu prema SEQ ID NO:20 i/ili signalnu domenu CD3 zeta sadrži aminokiselinsku sekvencu prema SEQ ID NO:24, 1 pri čemu je čovjek otporan na liječenje najmanje jednim kemoterapijskim sredstvom.
Levonorgestrel and indomethacin for use in a method for contraception and for reducing menstrual bleeding problems and for inducing amenorrhea, wherein levonorgestrel and indomethacin are released from an intrauterine delivery system over a prolonged period of time. 
Levonorgestrel i indometacin, namijenjeni upotrebi u postupku kontracepcije, sprječavanja ili suprimiranja neredovitog endometrijskog krvarenja i induciranja amenoreje, naznačeni time što se levonorgestrel i indometacin otpušta iz sustava za intrauterini unos u skladu s patentnim zahtjevom 1 kroz dulji vremenski period.
An organophosphate or carbamate for use in a method of treatment of farmed fish to combat infestation by multicellular ectoparasites with exoskeletons, which method comprises topically exposing farmed fish to a first and a second sea lice treatment agent sequentially, said first sea lice treatment agent being a carbamate or organophosphate and said second sea lice treatment agent being a pyrethroid or pyrethrin. wherein exposure to the first sea lice treatment agent is effected 10 minutes to 12 hours before exposure to the second sea lice treatment agent. 
PATENTNI ZAHTJEVI u Organofosfat ili karbamat za uporabu u postupku tretmana uzgajanih riba radi borbe protiv infestacije višestaničnim ektoparazitima s tvrdim vanjskim skeletom (egzoskelet), taj postupak obuhvaća uzastopni topikalni tretman uzgajanih riba s prvim i drugim sredstvom protiv morskih uši, to prvo sredstvo protiv morskih uši je karbamat ili organofosfat i drugo sredstvo protiv morskih uši je piretroid ili piretrin, pri čemu izloženost prvom sredstvu protiv morskih uši traje 10 minuta do 12 sati prije izlaganja drugom sredstvu protiv morskih uši.
The dispersion for the use of Claim 30, wherein the lymphoid malignancy is non-Hodgkin's lymphoma, chronic lymphoid leukemia, or acute lymphocytic leukemia. 
Disperzija za uporabu u skladu s patentnim zahtjevom 30, naznačena time, da je limfoidni maligni tumor ne-Hodgkinov limfom, kronična limfoidna leukemija ili akutna limfocitna leukemija.
A vaccine kit for concomitant or sequential administration comprising two multivalent immunogenic compositions for conferring protection in a host against disease caused by Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, and Haemophilus influenzae, said kit comprising a first container comprising: tetanus toxoid (TT), and 
Cjepivni komplet za istodobnu ili uzastopnu primjenu, naznačen time što sadrži dva polivalentna imunogena pripravka za postizanje zaštite kod domačina protiv bolesti koje uzrokuju bakterije Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, te Haemophilus influenzae, gdje navedeni komplet sadrži prvi spremnik, koji sadrži: tetanusni toksoid (TT), t>&
a mutated OmpT gene, wherein the mutated OmpT gene encodes an OmpT protein having reduced protease activity or is a knockout mutated OmpT gene. 
mutirani gen OmpT, pri čemu mutirani OmpT gen kodira OmpT protein sa smanjenom aktivnosti proteaze ili je nokaut mutirani OmpT gen.
An aqueous pharmaceutical formulation, preferably with pH between 3.4 and 4.6, comprising zinc and insulin glargine for use in providing a peakless long acting basal insulin in the treatment of Type I and Type II Diabetes Mellitus in a patient, wherein the concentration of insulin glargine is 250-700 U/mL being equimolar to 250-700 IU human insulin. 
Vodeni farmaceutski pripravak sa pH između 3.4 1 4.6 koji sadrži inzulin glargin naznačen time da je za uporabu u postupku za osiguravanje dugodjelujućeg bazalnog inzulina bez vrhunca u liječenju dijabetes melitusa tipa I i tipa IL, pri čemu pripravak sadrži 270 - 330 U/mL inzulin glargina.
as well as their corresponding N-hydroxysuccinimide ester or their pharmaceutically acceptable salts, hydrates, or hydrated salts, or the polymorphic crystalline structures of these compounds or their optical isomers, racemates, diastereomers or enantiomers. 
O o kao i odgovarajući N-hidroksisukcinimidilni esteri, ili njihove farmaceutski prihvatljive soli, hidrati ili hidrati soli, ili polimorfne kristalne strukture tih spojeva ili njihovih optičkih izomera, racemata, dijastereoizomera ili enantiomera.
Figs. 12-16 show a further embodiment of the building and method according to the invention. 
SL. 12-16 pokazuju daljnje uobličenje građevine i metode prema predmetnom izumu.
Magnetic optically variable pigments which can be used for the embodiment of the invention have been disclosed in U.S. Pat. No. 4,838,648; in EP 686,675 B1; as well as in WO 02/73250 A2 and in WO 03/00801 A2; the latter two describe the best suited pigments to solve the stated technical problem. 
Magnetski optički varijabilni pigmenti koji se mogu koristiti u utjelovljenjima sukladno predmetnom izumu opisani su u US 4,838,648; EP 686,675 B1; kao 1u WO 02/73250 A2 i WO 03/00301 A2; u zadnja dva dokumenta opisuju se najprikladnije vrste pigmenta za rješavanje navedenih tehničkih problema.
contacting a sample with a substrate of the cell death-stable enzyme activity wherein the substrate in conjugated to a detectable leaving group; and 
kontakta uzorka sa supstratom enzimske aktivnosti stabilne stanične smrti pri čemu je supstrat konjugiran na odlaznu skupinu koja se može otkriti; i
An oral formulation in tablet form according to claim 1, wherein the tablet further comprises a lubricant. 
Oralna formulacija u obliku tablete u skladu s patentnim zahtjevom 1, naznačena time što tableta dodatno sadrži mazivo.
Sample B: Milk containing 1 g/L of the light stabilising composition described in Example 1 
Uzorci A i C: mlijeko bez dodatka Uzorak B: mlijeko koje sadržava 1 g/L pripravka za stabiliziranje na svjetlo opisanog u primjeru 1
The tablet of embodiment 7 wherein the total weight of the first layer is 275 ± 75 mg. The tablet of embodiment 7 wherein the total weight of the first layer is greater than 225 mg. 
Tableta zahtjeva 6 gdje je ukupna masa prvog sloja 275 + 75 mg, prije svega veća od 225 mg, a posebno je 275 + 50 mg.
spray drying the whole mixture obtained (124), 
- > sušenja raspršivanjem cijele dobivene smjese (124),
The 1,1,1,2,3-pentachloropropane used for the preparation of 1,1,2,3-tetrachloropropene may be prepared by one of the aforementioned processes for preparing 1,1,1,2,3-pentachloropropane. In some embodiments, the crude 1,1,1,2,3-pentachloropropane reactor effluent from a reactor in which 1,1,1,2,3-pentachloropropane is formed is dehydrochlorinated directly, without prior purification and without added catalysts or reagents. 
Postupak iz patentnog zahtjeva 12, pri čemu se navedenim korakom zagrijavanja reakcijske smje stvara sirovi 1,1,1,2,3-pentakloropropan i gdje se sirovi 1,1,1,2,3-pentakloropropan koji se izljeva iz reaktora u kojem se 1,1,1,2,3-pentakloropropan stvara izravno dehidroklorira, bez prethodnog pročišćavanja i bez dodavanja katalizatora ili reagencija.
SGLT2, a 672 amino acid protein containing 14 membrane-spanning segments that is predominantly expressed in the early S1 segment of the renal proximal tubules, is likely to be the major transporter responsible for this reuptake. 
SGLT2, protein od 672 aminokiselina koji sadrži 14 segmenata koji se pružaju kroz membranu koji se pretežno eksprimira u ranom S1 segmentu bubrežnih proksimalnih tubula, je vjerojatno glavni transporter koji je odgovoran za ovo ponovno preuzimanje.
A space unit according to claim 2 or 3, characterized in that the seat portion (5b) is designed to comprise a space for sitting and a table space. 
Prostorna jedinica sukladno zahtjevima 2 ili 3, naznačena time, da je sjedeći dio (5b) dizajniran da obuhvaća prostor za sjedenje i prostor za stol.
The mouse of claim 1, wherein the humanized PD-1 polypeptide comprises amino acids 26-169 of a human PD-1 polypeptide. 
miš eksprimira polipeptid PD-1 iz endogenog gena Pdcd1, gdje polipeptid PD-1 sadrži ljudski slijed, gdje se postupak sastoji u
33.The modified sulfamidase or the sulfamidase composition according to any one of embodiments 1-17 and 32, for use in therapy. 
Modificirana sulfamidaza ili supstanca sulfamidaze sukladno bilo kojem od patentnih zahtjeva 1-6 i 14, za uporabu u liječenju.
A molecule according to claim 1 wherein the polyethylene glycol molecule is attached via a maleimide linkage. 
Molekula u skladu s patentnim zahtjevom 2, naznačena time što je molekula polietilen-glikola vezana preko maleimidne spojnice.
a polypeptide, which comprises the NS3 protein of the hepatitis C virus, or a fragment of said NS3 protein with capacity for inducing CD8+ and CD4+ responses. 
€) polipeptid, koji sadrži NS3 protein virusa hepatitisa C, ili fragment navedenog NS3 proteina sa kapacitetom za indukciju CD8+ i CD4+ odgovora.
L is PR'3 or NR"3, wherein R' is selected from alkyl, aryl and alkylaryl, and R" is selected from the group consisting of alkyl, aryl, and alkylaryl; and n is between 0 and 8. 
L se bira iz skupine koju čine PR! i NR",, gdje R' se bira iz skupine koju čine alkil, aril, alkilaril, a R" se bira iz skupine koju čine alkil, aril, i alkilaril;
The oral formulation according to anyone of claims 1 to 7 characterized by an improved absorption profile over the Medium Chain Triglycerides (MCT) formulation of inecalcitol. 
Oralna formulacija prema bilo kojem patentnom zahtjevu od 1 do 5, naznačena time da ima poboljšani apsorpcijski profil u odnosu na formulaciju inekalcitola sa srednjolančanim trigliceridima (MCT).
The coating of claim 10 produced from an aqueous slurry, wherein the aluminum powder comprises a particle size distribution characterized in that the 50th percentile of the particle size distribution has a diameter of between about 3.9 to 4.5 microns and the 90th percentile of the particle size distribution has a diameter of less than or equal to about 9.0 microns. 
Sastav obloge iz patentnog zahtjeva 7, pri čemu prah aluminija obuhvaća raspodjelu veličina čestica karakteriziranu na način da 50. percentila raspodjele veličine čestica ima promjer između 3.9 1 4.5 mikrometara i 90. percentila raspodjele veličine čestica ima promjer manji ili jednak 9.0 mikrometara.
The use of a method according to either or both of claims 13 and 14 for revamping a facility for the integrated production of urea and melamine. 
Primjena metode prema jednom ili oba zahtjeva 13 i 14 za modernizaciju pogona za integriranu proizvodnju uree i melamina.
A compound according to any of claim 1 to 9, wherein R2 and R'2, together with the nitrogen atom to which they are linked, form a thiomorpholinyl group. 
Spoj prema bilo kojem zahtjevu od 1 do 9, naznačen time da R2 1 R',, zajedno sa atomom dušika na koji su spojeni, formiraju tiomorfolinilnu skupinu.
Examples of compounds for the present invention include natural ecteinascidins, such as ecteinascidin 743 and other 1,4 bridged fused ecteinascidin compounds disclosed for example in U.S. Pat. Nos. 5,089,273, 5,478,932, 5,654,426, 5,721,362, 6,124,293, 5,149,804, Ser. No. 09/546,877, U.S. Pat. 
Primjeri spojeva za predstavljeni izum obuhvaćaju prirodne ekteinascidine, kao što je ekteinascidin 743 i drugel,4 premošćene fuzionirane spojeve ekteinascidina opisane npr. u US 5,089,273, US 5,478,932, US 5,654,426, US 5,721,362, US 6,124,293, US 5,149,804, US 09/546,877, US 5,985,876 i WO 01/77115.
Thus, generally, it is preferred for each lozenge component to be provided in a non-crystallizable form before blending with other components. 
Tako, generalno, poželjno je da svaka komponenta tablete bude osigurana u obliku koji ne kristalizira prije miješanja sa drugim komponentama.
A composition according to claim 32, wherein said pharmaceutical composition comprises said HDAC inhibitor at a concentration of -50 mg/mL. 
Sastav prema zahijevu 32, naznačen time, da spomenuti farmaceutski sastav sadrži HDAC inhibitor u koncentraciji od -50 mg/mL.
means for determining the mean offset of the symbols of the sequence. 
- - sredstvo (68) za određivanje srednjeg odlaznog pomaka simbola sekvence.
A kit comprising a first container comprising the lyophilized formulation according to claim 13 and a second container comprising a parenterally acceptable solvent for reconstitution thereof, and optionally a container comprising means for administrating the reconstituted solution to a patient in need thereof. 
17. Pribor koji obuhvaća ravnu posudu s lipofiliziranom formulacijom prema zahtjevu 141 drugu posudu s parenteralno prihvatljivim otapalom za rekonstituciju te, po želji, posudu sa sredstvom za primjenu rekonstituirane otopine u potrebitih pacijenata.
Figures 6A-C illustrate one way some of the components of device 10 can be integrated into a relatively small housing 200 (e.g., sheet metal) that can be installed on a vehicle or wherever else could be useful. 
Slike GA-C prikazuju jedan način na koji se neke od komponenata uređaja 10 mogu integrirati u jedno relativno malo kućište 200 (na primjer limeno) koje se može ugraditi na neko vozilo ili na bilo koje mjesto gdje to može biti korisno.
determining that the fractional concentration of the fetal DNA in the biological sample is above a fractional concentration corresponding to the calibration value when the first value is above the calibration value, or determining that the fractional concentration of the fetal DNA in the biological sample is below the fractional concentration corresponding to the calibration value when the first value is below the calibration value. 
Metoda prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, što se uspoređivanje prve vrijednosti s kalibracijskom vrijednosti sastoji od određivanja je li prva vrijednost prvog parametra iznad ili ispod kalibracijske vrijednosti, čime se određuje je li procijenjena frakcionalna koncentracija uzorka plazme iznad ili ispod granične frakcionalne koncentracije koja odgovara kalibracijskoj vrijednosti.
Pharmaceutical composition according to claim 12, wherein the dimethylfumarate is contained in a prolonged release matrix portion of a tablet and the teriflunomide is contained in a coating surrounding the matrix portion. 
Kombinacija za uporabu prema zahtjevu 21., naznačena time što je dimetilfumarat sadržan u dijelu matrice tablete s produljenim oslobađanjem i jedno sredstvo odabrano između teriflunomida, fingolimoda i lakvinimoda sadržano je u ovojnici koja okružuje dio matrice.
Significance criteria: ≥ 50% of maximum stimulation or inhibition Dopamine Transporter (DAT): 
Signifikantni kriterij: > 50% maksimalne stimulacije ili inhibicije (i) Dopamin transporter (DAT):
an antibody comprising the three heavy chain CDRs of sequence SEQ ID No. 
Cc) antitijela koje sadrži tri teška lanca CDRs sekvencije SEQ ID br.
Pharmaceutical composition comprising a pharmaceutical formulation including an amount of a PDE4 inhibitor, an amount of a HMG-CoA reductase inhibitor and at least one pharmaceutically acceptable auxiliary, wherein the PDE4 inhibitor is 2-{4-[(4aS, 8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl}-acetamide or a pharmaceutically acceptable salt thereof, the HMG-CoA reductase inhibitor is ATORVASTATIN or a pharmaceutically acceptable salt thereof, and wherein the first amount and the second amount together comprise an effective amount for the preventive or curative treatment of an inflammatory pulmonary disease. 
Farmaceutski sastav, naznačen time, da obuhvaća farmaceutsku formulaciju koja uključuje jednu količinu PDE4- inhibitora, jednu količinu inhibitora reduktaze HMG-CoA 1 barem jedno farmaceutski prihvatljivo pomoćno sredstvo, dok je PDEA-inhibitor odabran iz skupine koja sadrži ROFLUMILAST, farmaceutski prihvatljivu sol ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljivu sol ROFLUMILAST-N-oksida, gdje inhibitor reduktaze HMG-CoA je ATORVASTATIN ili njegova farmaceutski prihvatljiva sol, pri čemu prva količina 1 druga količina zajedno sastavljaju djelotvornu količinu za preventivno i kurativno liječenje upalne bolesti pluća.
Accordingly, the sugar replacement composition is added to sugar in concentrations up to e.g. 
Slijedom toga, kombinacija koja zamjenjuje šećer dodaje se šećeru u koncentracijama do npr.
The cumulative productivity and glucose consumption rate measured during this subsequent run are shown on FIGS. 
Ukupna produktivnost i stopa potrošnje glukoze koji su izmjerene tijekom zadnje runde prikazane su na Slikama 1 12.
Starting material (post-capture) 
Početni materijal (nakon lovljenja)
Polygraphic recordings were performed during 4 days to collect reference qualitative and quantitative data of sleep-wake control in each individual. 
Poligrafska su očitanja vršena tijekom 4 dana, kako bi se prikupili referentni kvalitativni i kvantitativni podaci o kontroli spavanja i budnosti kod svake individue.
The polyvinylpyrrolidone solution was added over a period of three minutes to the mixture containing clarithromycin and mixed in the granulator at 250 mL/min at the above settings. 
Otopina polivinilpirolidona se doda tijekom razdoblja od tri minute u smjesu koja sadrži klaritromicin i miješa se u granulatoru na 250 ml/min uz gore navedene uvjete.
A therapeutic antibody or antigen binding fragment of claim 3 wherein the binding of the antibody with hIL-13 depends upon the presence of an arginine residue at position 107 of SEQ. 
Terapijsko protutijelo, ili antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačen time što je navedeno protutijelo štakorsko, mišje, primatsko ili ljudsko protutijelo.
A compound according to the following formula (1), an enantiomer, diastereomer, tautomer, solvate, prodrug or pharmaceutical acceptable salt thereof wherein R is selected from the group consisting of COOR', CONR'R', tetrazolyl or H, with R' independently selected from the group consisting of H, lower alkyl; 
Spoj prema slijedećoj formuli (1), njegov enantiomer, diastereomer, tautomer ili farmaceutski prihvatljiva sol [image] gdje R je izabran iz grupe koju čini COOR6, CONR7R8, tetrazolil ili H, gdje je R6 nezavisno izabran iz grupe koju čini H, ili C1-6 alkil, i R7 i R8 međusobno nezavisno izabrani iz grupe koju čine H, C1-6 alkil, C1-6 haloalkil, C1-6 alkilen-R9, SO2-C1-6 alkil gdje je R9 izabran iz grupe koju čine COOH, OH, ili SO3H;
In a more preferred embodiment, the cysteine residue at position 565 of the AvPAL variant has been substituted by a serine residue. 
(1) AvPAL varijanta ima slijed SEQ ID NO: 10, gdje na poziciji 565 AvPAL varijanta ima serinski ostatak; ili